Top

Gepubliceerd in:

01-02-2010

De rol van presynaptische dopaminerge beeldvorming bij de ziekte van Parkinson

Auteur: Silvia Eshuis

Gepubliceerd in: Neuropraxis | Uitgave 1/2010

Samenvatting

De ziekte van Parkinson is een langzaam progressieve degeneratieve aandoening die gekenmerkt wordt door progressieve degeneratie van dopaminerge neuronen in de substantia nigra. De klassieke trias van klinische symptomen van de ziekte van Parkinson bestaat uit: bradykinesie, rigiditeit en rusttremor. In het begin van de ziekte kunnen deze symptomen nog subtiel zijn en kan het daarom lastig zijn om uitsluitend op basis daarvan de juiste diagnose te stellen.

vorige artikel De cognitieve en neurale basis van hallucinaties bij schizofrenie

volgende artikel Virtuele Psychiatrie?

Antonini, A., Vontobel, P., Psylla, M., Gunther, I., Maguire, P.R., Missimer, J. & Leenders, K.L. (1995). Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson’s disease. Archives of Neurology, 52, 1183–1190.PubMedCrossRef

Asenbaum, S., Brucke, T., Pirker, W., Podreka, I., Angelberger, P., Wenger, S., Wober, C., Muller, C. & Deecke, L. (1997). Imaging of dopamine transporters with iodine-123-beta-CIT and spect in Parkinson’s disease. Journal of Nuclear Medicine, 38, 1–6.PubMed

Benamer, H.T., Patterson, J., Wyper, D.J., Hadley, D.M., Macphee, G.J. & Grosset, D.G. (2000a). Correlation of Parkinson’s disease severity and duration with 123I-fp-cit spect striatal uptake. Movement Disorders, 15, 692–698.CrossRef

Benamer, T.S., Patterson, J., Grosset, D.G., Booij, J., Bruin, K. de, Royen, E. van, Speelman, J.D., Horstink, M.H., Sips, H.J., Dierckx, R.A., Versijpt, J., Decoo, D., Van Der, L.C., Hadley, D.M., Doder, M., Lees, A.J., Costa, D.C., Gacinovic, S., Oertel, W.H., Pogarell, O., Hoeffken, H., Joseph, K., Tatsch, K., Schwarz, J. & Ries, V. (2000b). Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-fp-cit spect imaging: the [123I]-fp-cit study group. Movement Disorders, 15, 503–510.CrossRef

Booij, J., Bergmans P., Winogrodzka, A., Speelman, J.D. & Wolters, E.C. (2001). Imaging of dopamine transporters with [123I]fp-cit spect does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson’s disease. Synapse, 39, 101–108.PubMedCrossRef

Booij, J., Tissingh, G., Boer, G.J., Speelman, J.D., Stoof, J.C., Janssen, A.G., Wolters, E.C. & Royen, E.A van. (1997). [123I]fp-cit spect shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 62, 133–140.CrossRef

Dhawan, V., Ma, Y.L., Pillai, V., Spetsieris, P., Chaly, T., Belakhlef, A., Margouleff, C. & Eidelberg, D. (2002). Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: Ratio method versus graphical approach. Journal of Nuclear Medicine, 43, 1324–1330.PubMed

Eidelberg, D., Takikawa, S., Dhawan, V., Chaly, T., Robeson, W., Dahl, R., Margouleff, D., Moeller, J.R., Patlak, C.S. & Fahn, S. (1993). Striatal F-18 Dopa Uptake - Absence of An Aging Effect. Journal of Cerebral Blood Flow and Metabolism 13, 881–888.PubMedCrossRef

Eshuis, S.A., Jager, P.L., Maguire, R.P., Jonkman, S., Dierckx, R.A. & Leenders, K.L. (2009). Direct comparison of fp-cit spect and f-dopa pet in patients with Parkinson’s disease and healthy controls. European. Journal of Nuclear Medicine and Molecular Imaging, 36, 454–462.PubMedCrossRef

Eshuis, S.A., Maguire, R.P., Leenders, K.L., Jonkman, S. & Jager, P.L. (2006). Comparison of fp-cit spect with f-dopa pet in patients with de novo and advanced Parkinson’s disease. Euopean. Journal of Nuclear Medicine and Molecular Imaging, 33, 200–209.CrossRef

Fearnley, J.M. & Lees, A.J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 114 (Pt 5), 2283–2301.PubMedCrossRef

Garnett, E.S., Nahmias, C. & Firnau, G. (1984). Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Canadian Journal of Neurological Science, 11, 174–179.

Goodman, M.M., Keil, R., Shoup, T.M., Eshima, D., Eshima, L., Kilts, C., Votaw, J., Camp, V.M., Votaw, D., Smith, E., Kung, M.P., Malveaux, E., Watts, R., Huerkamp, M., Wu, D., Garcia, E. & Hoffman, J.M. (1997). Fluorine-18-FPct: a pet radiotracer for imaging dopamine transporters. Journal of Nuclear Medicine, 38, 119–126.PubMed

Haaxma, C.A., Borm, G.F., Bloem, B.R. & Horstink, M.W.I.M. (2006). Gender differences in Parkinson’s disease. Movement Disorders, 21, S84.

Haycock, J.W., Becker, L., Ang, L., Furukawa, Y., Hornykiewicz, O. & Kish, S.J. (2003). Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. Journal of Neurochemistry, 87, 574–585.PubMedCrossRef

Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe E., Burghaus, L., Jacobs, A.H., Herholz, K. & Heiss, W.D. (2005). Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology, 65, 1716–1722.PubMedCrossRef

Hughes, A.J., Daniel, S.E., Ben Shlomo, Y. & Lees, A.J. (2002). The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 125, 861–870.PubMedCrossRef

Hughes, A.J., Daniel, S.E., Blankson, S. & Lees, A.J. (1993). A Clinicopathological Study of 100 Cases of Parkinson’s-Disease. Archives of Neurology, 50, 140–148.PubMedCrossRef

Ishikawa, T., Dhawan, V., Kazumata, K., Chaly, T., Mandel, F., Neumeyer, J., Margouleff, C., Babchyck, B., Zanzi, I. & Eidelberg, D. (1996). Comparative nigrostriatal dopaminergic imaging with iodine-123-beta cit/fpspect and fluorine-18-fdopa/pet. Journal of Nuclear Medicine, 37, 1760–1765.PubMed

Ito, Y., Fujita, M., Shimada, S., Watanabe, Y., Okada, T., Kusuoka, H., Tohyama, M. & Nishimura, T. (1999). Comparison between the decrease of dopamine transporter and that of l-dopa uptake for detection of early to advanced stage of Parkinson’s disease in animal models. Synapse, 31, 178–185.PubMedCrossRef

Kaasinen, V., Nurmi, E., Bruck, A., Bergman, J., Solin, O. & Rinne, J.O. (2001). Increased frontal [F-18]fluorodopa uptake in early Parkinson’s Disease: sex differences in the prefrontal cortex. Brain, 124, 1125–1130.PubMedCrossRef

Kazumata, K., Dhawan, V., Chaly, T., Antonini, A., Margouleff, C., Belakhlef, A., Neumeyer, J. & Eidelberg, D. (1998). Dopamine transporter imaging with fluorine-18-FPCIT and pet. Journal of Nuclear Medicine, 39, 1521–1530.PubMed

Kish, S.J., Zhong, X.H., Hornykiewicz, O. & Haycock, J.W. (1995). Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Annals of Neurology, 38, 260–264.PubMedCrossRef

Koerts, J., Leenders, K.L., Koning, M., Portman, A.T. & Beilen, M. van (2007). Striatal dopaminergic activity (fdopa-pet) associated with cognitive items of a depression scale (madrs) in Parkinson’s disease. European Journal of Neuroscience, 25, 3132–3136.PubMedCrossRef

Kuhl, D.E., Minoshima, S., Fessler, J.A., Frey, K.A., Foster, N.L., Ficaro, E.P., Wieland, D.M. & Koeppe, R.A. (1996). In vivo mapping of cholinergic terminals in normal aging, Alzheimers disease, and Parkinson’s disease. Annals of Neurology, 40, 399–410.PubMedCrossRef

Laakso, A., Vilkman, H., Bergman, J., Haaparanta, M., Solin, O., Syvalahti, E., Salokangas, R.K.R. & Hietala, J. (2002). Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biological Psychiatry, 52, 759–763.PubMedCrossRef

Lavalaye, J., Booij, J., Reneman, L., Habraken, J.B. & van Royen, E.A. (2000). Effect of age and gender on dopamine transporter imaging with [123I]FP- CIT Spet in healthy volunteers. Europan Journal of Nuclear Medicine, 27, 867–869.CrossRef

Lee, C.S., Samii, A., Sossi, V., Ruth, T.J., Schulzer, M., Holden, J.E., Wudel, J., Pal, P.K., Fuente-Fernandez, R., Calne, D.B. & Stoessl, A.J. (2000). In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Annals of Neurology, 47, 493–503.PubMedCrossRef

Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Nahmias, C., Jones, T. & Marsden, C.D. (1986). Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry, 49, 853–860.CrossRef

Marek, K.L., Seibyl, J.P., Zoghbi, S.S., Zea-Ponce, Y., Baldwin, R.M., Fussell, B., Charney, D.S., Dyck, C. van, Hoffer, P.B. & Innis, R.P. (1996). [123I] beta-cit/spect imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology, 46, 231–237.PubMedCrossRef

Martin, W.R.W., Palmer, M.R., Patlak, C.S. & Calne, D.B. (1989). Nigrostriatal Function in Humans Studied with Positron Emission Tomography. Annals of Neurology, 26, 535–542.PubMedCrossRef

Morrish, P.K., Sawle, G.V. & Brooks, D.J. (1995). Clinical and [18F] dopa pet findings in early Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 59, 597–600.CrossRef

Niznik, H.B., Fogel, E.F., Fassos, F.F. & Seeman, P. (1991). The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. Journal of Neurochemistry, 56, 192–198.PubMedCrossRef

Ota, M., Yasuno, F., Ito, H., Seki, C., Nozaki, S., Asada, T. & Suhara, T. (2006). Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]dopa. Life Science, 79, 730–736.CrossRef

Paulus, W. & Jellinger, K. (1991). The neuropathologic basis of different clinical subgroups of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology, 50, 743–755.PubMedCrossRef

Pirker, W. (2003). Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Movement Disorders, 18, Supplement 7, S43–S51.PubMedCrossRef

Ryding, E., Lindstrom, M., Bradvik, B., Grabowski, M., Bosson, P., Traskman-Bendz, L. & Rosen, I. (2004). A new model for separation between brain dopamine and serotonin transporters in I-123-beta-cit spect measurements: normal values and sex and age dependence. European Journal of Nuclear Medicine and Molecular Imaging, 31, 1114–1118.PubMedCrossRef

Sawle, G.V., Colebatch, J.G., Shah, A., Brooks, D.J., Marsden, C.D. & Frackowiak, R.S.J. (1990). Striatal Function in Normal Aging - Implications for Parkinson’s-Disease. Annals of Neurology, 28, 799–804.PubMedCrossRef

Seibyl, J.P., Marek, K., Sheff, K., Zoghbi, S., Baldwin, R.M., Charney, D.S. Dyck, C.H. van & Innis, R.B. (1998). Iodine-123-beta-cit and iodine-123-fpcit spect measurement of dopamine transporters in healthy subjects and Parkinson’s patients. Journal of Nuclear Medicine, 39, 1500–1508.PubMed

Seibyl, J.P., Marek, K.L., Quinlan, D., Sheff, K., Zoghbi, S., Zea-Ponce, Y., Baldwin, R.M., Fussell, B., Smith, E.O., Charney, D.S., et al. (1995). Decreased single-photon emission computed tomographic [123I]beta-cit striatal uptake correlates with symptom severity in Parkinson’s disease. Annals of Neurology, 38, 589–598.PubMedCrossRef

Staley, J.K., Krishnan-Sarin, S., Zoghbi, S., Tamagnan, G., Fujita, M., Seibyl, J.P., Maciejewski, P.K., O’Malley, S. & Innis, R.B. (2001). Sex differences in [I-123]beta-cit spect measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse, 41, 275–284.PubMedCrossRef

Tissingh, G., Bergmans, P., Booij, J., Winogrodzka, A., Royen, E.A. van, Stoof, J.C. & Wolters, E.C. (1998). Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-cit spect. Journal of Neurology, 245, 14–20.PubMedCrossRef

Vingerhoets, F.J.G., Snow, B.J., Schulzer, M., Morrison, S., Ruth, T.J., Holden, J.E., Cooper, S. & Calne, D.B. (1994). Reproducibility of Fluorine-18-6-Fluorodopa Positron Emission Tomography in Normal Human-Subjects. Journal of Nuclear Medicine, 35, 18–24.PubMed

Volkow, N.D., Ding, Y.S., Fowler, J.S., Wang, G.J., Logan, J., Gatley, S.J., Hitzemann, R., Smith, G., Fields, S.D. & Gur, R. (1996). Dopamine transporters decrease with age. C 37, 554–559.

Weintraub, D., Newberg, A.B., Cary, M.S., Siderowf, A.D., Moberg, P.J., Kleiner-Fisman, G., Duda, J.E., Stern, M.B., Mozley, D. & Katz, I.R. (2005). Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. Journal of Nuclear Medicine, 46, 227–232.PubMed

Winogrodzka, A., Bergmans, P., Booij, J., Royen, E.A. van, Stoof, J.C. & Wolters, E.C. (2003). [(123)I]beta-cit spect is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 74, 294–298.CrossRef

Zigmond, M.J., Berger, T.W., Grace, A.A. & Stricker, E.M. (1989). Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Molecular and Chemical Neuropathology, 10, 185–200.PubMedCrossRef

Titel: De rol van presynaptische dopaminerge beeldvorming bij de ziekte van Parkinson
Auteur: Silvia Eshuis
Publicatiedatum: 01-02-2010
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 1/2010
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/s12474-010-0003-4

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2010

Woorden vooraf

Signalement

De cognitieve en neurale basis van hallucinaties bij schizofrenie

Virtuele Psychiatrie?